Sartorius Stedim Biotech (DIM) AGM 2026 summary

Opening remarks and agenda

• Chairman Dr. Michael Grosse welcomed shareholders, introduced board members, and confirmed a 93.8% quorum for the meeting.

• Agenda and resolutions were published in official bulletins, included board and auditor reports, and covered both ordinary and extraordinary sessions.

• The meeting included ratification of Dr. Michael Grosse as Director and was divided into ordinary and extraordinary sessions.

Board and executive committee updates

• Michael Grosse introduced himself as the new Chairman, emphasizing his 20 years of management experience in engineering, pharmaceuticals, and food packaging.

• Emphasized the importance of technological expertise and adaptability in a regulated environment.

Financial performance review

• 2025 sales revenue grew 9.6% in constant currencies to €2,967 million, with EBITDA margin improving to 30.8%.

• Underlying EBITDA rose 17% to €914 million.

• Underlying earnings per share increased from €3.49 to €4.40 year-on-year.

• Investments totaled €393 million, focusing on global manufacturing and R&D expansion, with a 13.3% capex ratio.